

Policy #	Policy Name	Brief Description of Policy Change
UM ONC_1043	Tarceva (Erlotinib)	Annual Review
UM ONC_1063	Oncaspar (pegaspargase)	Annual Review
UM ONC_1179	Abraxane (nab-paclitaxel)	Annual Review
UM ONC_1204	Caprelsa (vandetarib)	Annual Review
UM ONC_1226	Zaltrap (ziv-aflibercept)	Annual Review
UM ONC_1232	Stivarga (regorafenib)	Annual Review
UM ONC_1238	Kadcyla (ado-trastuzumab emtansine)	Annual Review
UM ONC_1270	Blincyto (blinatumomab)	Annual Review
UM ONC_1290	Yondelis (trabectedin)	Annual Review
UM ONC_1352	Asparlas (calaspargase pegol-mknl)	Annual Review
UM ONC_1373	Endari (l-glutamine)	Annual Review
UM ONC_1375	Adakveo (crizanlizumab)	Annual Review
UM ONC_1393	Sarclisa (isatuximab-irfc)	Annual Review
UM ONC_1408	Zepzelca (lurbinectedin)	Annual Review
UM ONC_1420	Margenza (margetuximab-cmkb)	Annual Review
UM ONC_1429	Abecma (idecabtagene vicleucel)	Annual Review
UM ONC_1460	Carvykti (ciltacabtagene autoleucel)	Annual Review
UM ONC_1462	Opdualag (nivolumab and relatlimab-rmbw)	Annual Review
UM ONC_1472	Adstiladrin (nadofaragene firadenovec-vncg)	Annual Review
UM ONC_1473	Krazati (adagrasib)	Annual Review
UM ONC_1474	Lunsumio (mosunetuzumab-axgb)	Annual Review
UM ONC_1475	Rezlidhia (olutasidenib)	Annual Review

